[CH3:1][N:2]([CH3:6])[C:3](Cl)=[O:4].[OH:7][C:8]([CH3:38])([CH3:37])[CH2:9][C@@:10]1([C:31]2[CH:36]=[CH:35][CH:34]=[CH:33][CH:32]=2)[O:15][C:14](=[O:16])[N:13]([C@H:17]([C:19]2[CH:24]=[CH:23][C:22]([CH:25]3[CH2:30][CH2:29][NH:28][CH2:27][CH2:26]3)=[CH:21][CH:20]=2)[CH3:18])[CH2:12][CH2:11]1.N1C=CC=CC=1.N>CN(C)C=O>[CH3:1][N:2]([CH3:6])[C:3]([N:28]1[CH2:29][CH2:30][CH:25]([C:22]2[CH:21]=[CH:20][C:19]([C@@H:17]([N:13]3[CH2:12][CH2:11][C@:10]([CH2:9][C:8]([OH:7])([CH3:37])[CH3:38])([C:31]4[CH:32]=[CH:33][CH:34]=[CH:35][CH:36]=4)[O:15][C:14]3=[O:16])[CH3:18])=[CH:24][CH:23]=2)[CH2:26][CH2:27]1)=[O:4]Dimethylcarbamoyl chloride (26 μL) was added to a solution of (S)-6-(2-hydroxy-2-methyl-propyl)-6-phenyl-3-[(S)-1-(4-piperidin-4-yl-phenyl)-ethyl]-[1,3]oxazinan-2-one (120 mg) and pyridine (40 μL) in N,N-dimethylformamide (2 mL) at room temperature. The solution was stirred at room temperature for 5 h, before another portion of dimethylcarbamoyl chloride (26 μL) and pyridine (20 μL) were added. The solution was stirred at room temperature overnight. Then, diluted aqueous ammonia solution was added and the resulting mixture was concentrated under reduced pressure. The residue was purified by HPLC on reversed phase (MeOH/H2O/NH3) to afford the title compound.